Peer Review reports
From: Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer
| Original Submission | ||
|---|---|---|
| 16 Jun 2023 | Submitted | Original manuscript |
| 9 Dec 2023 | Reviewed | Reviewer Report |
| 29 Dec 2023 | Reviewed | Reviewer Report |
| 11 Jan 2024 | Author responded | Author comments - Xiaoyan Liu |
| Resubmission - Version 2 | ||
| 11 Jan 2024 | Submitted | Manuscript version 2 |
| 12 Jan 2024 | Author responded | Author comments - Xiaoyan Liu |
| Resubmission - Version 3 | ||
| 12 Jan 2024 | Submitted | Manuscript version 3 |
| 22 Jan 2024 | Author responded | Author comments - Xiaoyan Liu |
| Resubmission - Version 4 | ||
| 22 Jan 2024 | Submitted | Manuscript version 4 |
| 31 Jan 2024 | Reviewed | Reviewer Report |
| Resubmission - Version 5 | ||
| Submitted | Manuscript version 5 | |
| Publishing | ||
| 11 Feb 2024 | Editorially accepted | |
| 21 Feb 2024 | Article published | 10.1186/s12885-024-11992-6 |
You can find further information about peer review here.